Content for healthcare professionals only

Content for healthcare professionals only

Content for healthcare professionals only

View all platforms

Medical Education
Home
Learning Hub
Publication Synopses
Contact Us
About Us

Content for healthcare professionals only

Home

Home

Heart Failure

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice

0.75 AMA PRA Credit

Published: 17/02/2022

Recall the efficacy and safety of existing HCM treatments
Summarise results from ongoing trials with experimental treatments
Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

See more

Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021

Hypertrophic Cardiomyopathy in Review: Highlights from HFA 2021

0.50 AMA PRA Credit

Published: 04/11/2021

Identify patients likely to benefit from invasive procedures versus pharmacological treatment
Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening

See more

Heart Failure

The 2022 ACC HF Guidelines: What Do They Mean for Your Practice?

The 2022 ACC HF Guidelines: What Do They Mean for Your Practice?

Not accredited

Published: 09/06/2022

Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
Compare updates from the ACC with the 2021 ESC HF guidelines
Recall guideline recommendations for the initiation of foundational therapy for heart failure
Adopt foundational GMDT early in the disease course
Postulate how ejection fraction will be used in future trials and in future guidelines
Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF

See more

The Advancing Management of Transthyretin Amyloidosis

Julian Gillmore Martha Grogan Laura Obici et al

1.00 EBAC

Published: 16/10/2023

To differentiate ATTR phenotypes based on presenting signs and symptoms.
To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
To recall how to identify disease progression across ATTR-cm.
To describe the different disease modifying treatments for ATTR including novel agents.

See more

Heart Failure

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure

Scott Solomon John JV McMurray Carolyn Lam et al

1.00 EBAC

Published: 08/09/2022

Recall the results of key trials in HFmrEF in different patients' sub-groups
Describe how SGLT-2 inhibitors can be used across the range of LVEF
Apply emerging diagnostic approaches for HFpEF and HFmrEF
Implement best-practice strategies across the range of LVEF

See more

Next Steps in Heart Failure: Changing Paradigms in Therapy to Unmet Needs

Changing Paradigms in Therapy to Unmet Needs

Javed Butler Clyde W Yancy Faiez Zannad et al

1.00 EBAC

Published: 26/10/2022

Recall the utility of EF in heart failure treatment, patient selection and treatment response
Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
Incorporate quality of life measures for assessing therapeutic efficacy in HF
Recall outcomes from heart failure trials from recent congress and publications and their impact on practice

See more